Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Treasury Shares (2017 - 2025)

Historic Treasury Shares for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $1.4 million.

  • Puma Biotechnology's Treasury Shares fell 47.39% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 47.39%. This contributed to the annual value of $1.3 million for FY2024, which is 2064.79% down from last year.
  • As of Q3 2025, Puma Biotechnology's Treasury Shares stood at $1.4 million, which was down 47.39% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Treasury Shares ranged from a high of $2.5 million in Q1 2021 and a low of $1.3 million during Q4 2024
  • Moreover, its 5-year median value for Treasury Shares was $1.9 million (2025), whereas its average is $1.8 million.
  • In the last 5 years, Puma Biotechnology's Treasury Shares plummeted by 2453.28% in 2021 and then surged by 2432.58% in 2023.
  • Puma Biotechnology's Treasury Shares (Quarter) stood at $1.4 million in 2021, then increased by 7.32% to $1.5 million in 2022, then increased by 8.2% to $1.6 million in 2023, then dropped by 20.65% to $1.3 million in 2024, then increased by 5.38% to $1.4 million in 2025.
  • Its Treasury Shares stands at $1.4 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.9 million for Q1 2025.